Multiparametric PET/CT in oncology

Cancer Imaging

Volumn 12, Issue 2, 2012, Pages 336-344

  Singh, Dalveer ^a   Miles, Kenneth ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Computed tomography texture analysis; Dynamic contrast enhanced computed tomography; Fluorodeoxyglucose positron emission tomography computed tomography; Multiparametric; Oncology imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADRENAL TUMOR; ANGIOGENESIS; BLOOD FLOW; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; GLUCOSE METABOLISM; HUMAN; ONCOLOGY; PHENOTYPE; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84867908116     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.9007     Document Type: Review

References (56)

1. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364. doi:10.1148/radiol.10091760. PMid:20656830.
2. Miles KA. PET/CT in oncology: making the most of CT. Cancer Imaging 2008; 8(A): S87-S93. doi:10.1102/1470-7330.2008.9015. PMid:18852084.
3. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004; 45: 1431-1434. PMid:15347707.
4. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200. doi:10.1007/s00259-009-1297-4. PMid:19915839.
5. Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008; 49: 1804-1808. doi:10.2967/jnumed.108.054239. PMid:18927325.
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247. doi:10.1016/j.ejca.2008.10.026. PMid:19097774.
7. Sahdev A, Willatt J, Francis IR, Reznek RH. The indeterminate adrenal lesion. Cancer Imaging 2010; 10: 102-113. PMid:20299300.
8. Miles KA. Molecular imaging with dynamic contrast-enhanced computed tomography. Clin Radiol 2010; 65: 549-556. doi:10.1016/j.crad.2010.04.007. PMid:20541654.
9. Petralia G, Bonello L, Viotti S, Preda L, d'Andrea G, Bellomi M. CT perfusion in oncology: how to do it. Cancer Imaging 2010; 10: 8-19. PMid:20159664.
10. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008; 49: 517-523. doi:10.2967/jnumed.107.048504. PMid:18344436.
11. Goh V, Ng QS, Miles K. Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol 2012; 47: 2-4. doi:10.1097/RLI.0b013e318229ff3e. PMid:21808202.
12. Miles KA, Lee TY, Goh V, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 2012; 22: 1430-1441. doi:10.1007/s00330-012-2379-4. PMid:22367468.
13. Ganeshan B, Miles KA, Young RC, Chatwin CR. In search of biologic correlates for liver texture on portal-phase CT. Acad Radiol 2007; 14: 1058-1068. doi:10.1016/j.acra.2007.05.023. PMid:17707313.
14. Ganeshan B, Miles KA, Young RC, Chatwin CR. Hepatic entropy and uniformity: additional parameters that can potentially increase the effectiveness of contrast enhancement during abdominal CT. Clin Radiol 2007; 62: 761-768. doi:10.1016/j.crad.2007.03.004. PMid:17604764.
15. Ganeshan B, Miles KA, Young RC, Chatwin CR. Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. Acad Radiol 2007; 14: 1520-1530. doi:10.1016/j.acra.2007.06. 028. PMid:18035281.
16. Ganeshan B, Miles KA, Young RC, Chatwin CR. Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver. Eur J Radiol 2009; 70: 101-110. doi:10.1016/j.ejrad.2007.12.005. PMid:18242909.
17. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 2012; 22: 796-802. doi:10.1007/s00330-011-2319-8. PMid:22086561.
18. Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 2012; 67: 157-164. doi:10.1016/j.crad.2011.08.012. PMid:21943720.
19. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011; 261: 165-171. doi:10.1148/radiol.11110264. PMid:21813743.
20. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med 2012; 53: 693-700. doi:10.2967/jnumed.111.099127. PMid:22454484.
21. Veit-Haibach P, Treyer V, Strobel K, et al. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging 2010; 35: 528-536. doi:10.1007/s00261-009-9559-y. PMid:19593563.
22. Groves AM, Wishart GC, Shastry M, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging 2009; 36: 416-421. doi:10.1007/s00259-008-0948-1. PMid:18818917.
23. Bisdas S, Spicer K, Rumboldt Z. Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positronemission tomography/CT imaging. AJNR Am J Neuroradiol 2008; 29: 1376-1381. doi:10.3174/ajnr.A1111. PMid:18483187.
24. Ganeshan B, Hosur A, Skogen K, Tasker F, Dizdarevic S, Miles K. Multiparametric FDG-PET CT in thoracic malignancies: opportunities for combined prognostic imaging biomarkers. Presented at: UK Radiological Congress, 10-12 June, 2012, Liverpool, UK. PMid:22826419.
25. Ganeshan B, Burnand K, Young R, Chatwin C, Miles K. Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer. Invest Radiol 2011; 46: 160-168. doi:10.1097/RLI. 0b013e3181f8e8a2. PMid:21102348.
26. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008; 8: 81-86. doi:10.1102/1470-7330.2008.0011. PMid:18390391.
27. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49(Suppl 2): 24S-42S. doi:10.2967/jnumed.107.047258. PMid:18523064.
28. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9(Suppl 5): 4-9. doi:10.1634/theoncologist.9-90005-4. PMid:15591417.
29. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 22-28. doi:10.1007/s00259-005- 1932-7. PMid:16180030.
30. Shastry M, Miles KA, Win T, et al. Integrated 18F-fluorodeoxyglucose- positron emission tomography/dynamic con-trast- enhanced computed tomography to phenotype non-small cell lung carcinoma. Mol Imaging 2012; 11: 1-8. PMid:22480786.
31. Miles KA, Williams RE, Yu D, Griffiths MR. Demonstrating intertumoural differences in vascular-metabolic phenotype with dynamic contrast-enhanced CT-PET. Int J Mol Imaging 2011; article 679473. PMid:21629862.
32. Goh V, Engledow A, Rodriguez-Justo M, et al. The flow-metabolic phenotype of primary colorectal cancer: assessment by integrated 18F-FDG PET/perfusion CT with histopathologic correlation. J Nucl Med 2012; 53: 687-692. doi:10.2967/jnumed.111.098525. PMid:22454485.
33. Sauter AW, Winterstein S, Spira D, et al. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med 2012; 53: 521-529. doi:10.2967/jnumed.111.097865. PMid:22414637.
34. Cochet A, Pigeonnat S, Khoury B, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors. J Nucl Med 2012; 53: 512-520. doi:10.2967/jnumed.111.096834. PMid:22343501.
35. Ganeshan B, Ziauddin Z, Goh VJ, et al. Quantitative imaging biomarkers from PET/CT as potential correlates for angiogenesis and hypoxia in colorectal cancer. Presented at: European Congress of Radiology, March 1-5, 2012, Vienna; SS 1801a: B-0876. PMid:22826419.
36. Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology 2009; 250: 523-530. doi:10.1148/radiol.2502080219. PMid:19188319.
37. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006; 238: 970-977. doi:10.1148/radiol.2383042164. PMid:16505394.
38. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol 2011; 197: 209-216. doi:10.2214/AJR.10.5342. PMid:21701032.
39. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12. doi:10.1097/JTO.0b013e31815e6d6b. PMid:18166834.
40. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009; 21: 1008-1015. doi:10.1097/MEG.0b013e328323d6fa. PMid:19352191.
41. Roedl JB, Sahani DV, Colen RR, Fischman AJ, Mueller PR, Blake MA. Tumour length measured on PET/CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol 2008; 18: 2833-2840. doi:10.1007/s00330-008-1078-7. PMid:18651155.
42. Roedl JB, Sahani DV, Colen RR, Fischman AJ, Mueller PR, Blake MA. Tumour length measured on PET/CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol 2008; 18: 2833-2840. doi:10.1007/s00330-008-1078-7. PMid:18651155.
43. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(Suppl 1): 122S-150S. doi:10.2967/jnumed.108.057307. PMid:19403881.
44. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759. doi:10.1200/JCO.2006.07.3049. PMid:17470865.
45. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: 1470-1478. doi:10.2214/AJR.09.3456. PMid:20489085.
46. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010; 194: 157-165. doi:10.2214/AJR.09.2941. PMid:20028918.
47. Bisdas S, Rumboldt Z, Wagenblast J, et al. Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements. AJNR Am J Neuroradiol 2009; 30: 793-799. doi:10.3174/ajnr.A1449. PMid:19351906.
48. Zima A, Carlos R, Gandhi D, Case I, Teknos T, Mukherji SK. Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? AJNR Am J Neuroradiol 2007; 28: 328-334. PMid:17297007.
49. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-1356. doi:10.1016/S0360-3016(03)00764-8. PMid:14630273.
50. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 2009; 193: 1090-1096. doi:10.2214/AJR.08.1367. PMid:19770333.
51. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007; 244: 486-493. doi:10.1148/radiol.2442061189. PMid:17641369.
52. Gandhi D, Chepeha DB, Miller T, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 2006; 27: 101-106. PMid:16418366.
53. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005; 234: 785-792. doi:10.1148/radiol.2343040286. PMid:15734934.
54. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47: 11-17. doi:10.1097/RLI. 0b013e3182199bb5. PMid:21512396.
55. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147. doi:10.1038/nm988. PMid:14745444.
56. Ganeshan B, Miles KA, Young RC, Chatwin CR, Gurling HM, Critchley HD. Three-dimensional textural analysis of brain images reveals distributed grey-matter abnormalities in schizophrenia. Eur Radiol 2010; 20: 941-948. doi:10.1007/s00330-009-1605-1. PMid:19760235.